Unleashing the Power of Tregs

Three Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic diseases

Enhancing regulatory T cells (Tregs) through multiple product modalities

We are a clinical-stage company focused on developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

News

Keep up-to-date with the latest news about Coya Therapeutics.

Coya Therapeutics, Inc. Announces Pricing of $15.25 Million Initial Public Offering

Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Announces Peer-Reviewed Publication of its First- in-Class Regulatory T cell derived Exosomes and Their Therapeutic Potential in Neurodegeneration and Inflammation-Related Diseases